STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #173 by analyst upside · 2026-08-14
TENX
Tenax Therapeutics, Inc.
Healthcare · Market Cap $68M · P/E 0x
ANALYST PRICE TARGET
+539.3%
implied upside to consensus target
Current Price $1.83
Consensus Target $11.7
Bull Target $36.0
Bear Target $4.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
3
Sell
0
52-Week Low $1.31
52-Week High $19.4
YTD Return -83.4%
FUNDAMENTALS
Market Cap $68M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.48
PEG Ratio 1.44
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.31
52-Week High $19.4
Current Price $1.83
Bear Target $4.0
Bull Target $36.0
● Now $1.83 ● Target $11.7
TRADING DATA
Avg Volume 3.0M
YTD Return -83.4%
Analyst Count 10
Consensus Buy
Upside to Target +539.3%
Last Updated 2026-08-14

ANALYST SUMMARY

Tenax Therapeutics, Inc. (TENX) is currently trading at $1.83 with a Wall Street consensus price target of $11.7, implying potential upside of 539.3% over the next 12 months. 10 analysts currently cover TENX, with a consensus rating of Buy - 70% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $36.0, while the most cautious has a target of $4.0.

TENX operates in the Healthcare sector with a market capitalisation of $68M. The stock is down 83.4% year-to-date and is currently trading near the lower end of its 52-week range of $1.31 – $19.4.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TENX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Overweight → Overweight 2026-06-12 14% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-03-17 40% win rate (10 calls)
Guggenheim - Reiterated
Buy → Buy 2026-03-16 62% win rate (8 calls)
Guggenheim - Reiterated
Buy → Buy 2025-12-17 62% win rate (8 calls)
Piper Sandler ● Initiated
Overweight 2025-09-08 14% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2025-08-14 62% win rate (8 calls)
Leerink Partners ● Initiated
Outperform 2024-10-24 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
32
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →